DK1177289T3 - Rekombinant blodpladecollagenreceptor glycopotein VI og dets farmaceutiske anvendelse - Google Patents

Rekombinant blodpladecollagenreceptor glycopotein VI og dets farmaceutiske anvendelse

Info

Publication number
DK1177289T3
DK1177289T3 DK00927035T DK00927035T DK1177289T3 DK 1177289 T3 DK1177289 T3 DK 1177289T3 DK 00927035 T DK00927035 T DK 00927035T DK 00927035 T DK00927035 T DK 00927035T DK 1177289 T3 DK1177289 T3 DK 1177289T3
Authority
DK
Denmark
Prior art keywords
glycopotein
pharmaceutical use
collagen receptor
recombinant platelet
platelet collagen
Prior art date
Application number
DK00927035T
Other languages
Danish (da)
English (en)
Inventor
Kenneth J Clemetson
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1177289(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1177289T3 publication Critical patent/DK1177289T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/018—Platelets
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/222—Platelet disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
DK00927035T 1999-05-07 2000-04-25 Rekombinant blodpladecollagenreceptor glycopotein VI og dets farmaceutiske anvendelse DK1177289T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99109094 1999-05-07
PCT/EP2000/003683 WO2000068377A1 (en) 1999-05-07 2000-04-25 Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use

Publications (1)

Publication Number Publication Date
DK1177289T3 true DK1177289T3 (da) 2008-08-11

Family

ID=8238132

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00927035T DK1177289T3 (da) 1999-05-07 2000-04-25 Rekombinant blodpladecollagenreceptor glycopotein VI og dets farmaceutiske anvendelse
DK11001216T DK2341141T3 (en) 1999-05-07 2000-04-25 Antibodies to recombinant platelet kollagenreceptorglycoprotein VI

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11001216T DK2341141T3 (en) 1999-05-07 2000-04-25 Antibodies to recombinant platelet kollagenreceptorglycoprotein VI

Country Status (26)

Country Link
US (5) US7928066B1 (pl)
EP (3) EP1177289B1 (pl)
JP (2) JP5480457B2 (pl)
KR (1) KR100703592B1 (pl)
CN (1) CN1253569C (pl)
AR (1) AR023848A1 (pl)
AT (1) ATE393223T1 (pl)
AU (1) AU775952B2 (pl)
BR (1) BRPI0010325B1 (pl)
CA (1) CA2372515C (pl)
CY (2) CY1108190T1 (pl)
CZ (1) CZ302693B6 (pl)
DE (1) DE60038675T2 (pl)
DK (2) DK1177289T3 (pl)
ES (2) ES2304347T3 (pl)
HK (1) HK1045714B (pl)
HU (1) HUP0201049A2 (pl)
MX (1) MXPA01011274A (pl)
NO (1) NO333408B1 (pl)
PL (1) PL204449B1 (pl)
PT (2) PT1177289E (pl)
RU (1) RU2287580C2 (pl)
SI (1) SI1177289T1 (pl)
SK (1) SK15762001A3 (pl)
WO (1) WO2000068377A1 (pl)
ZA (1) ZA200110071B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1177289B1 (en) * 1999-05-07 2008-04-23 Sanofi-Aventis Deutschland GmbH Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use
US6245527B1 (en) 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001016321A1 (en) * 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (en) * 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
EP1406929A2 (en) * 2001-07-18 2004-04-14 MERCK PATENT GmbH Glycoprotein vi fusion proteins
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
DE102004017295A1 (de) * 2004-04-05 2005-11-03 Zlb Behring Gmbh Verbindungen, welche die Entfernung von Rezeptoren von Zelllmembranen bewirken oder verhindern, und Verfahren zu ihrem Nachweis
WO2005111083A2 (en) 2004-04-29 2005-11-24 Otsuka Pharmaceutical Co., Ltd. Antibodies specific for glycoprotein vi and methods of producing these antibodies
US7645592B2 (en) 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
MX2010004537A (es) * 2007-10-31 2010-05-20 Otsuka Pharma Co Ltd Usos de un inhibidor glucoproteina vi (gpvi).
EP3150750B1 (en) 2011-04-08 2018-12-26 Prognosys Biosciences, Inc. Peptide constructs and assay systems
EP3184544A1 (en) * 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ287472B6 (en) 1993-07-01 2000-12-13 Merck Patent Gmbh Purified protein, process of its preparation and use as well as pharmaceutical preparation based thereon
AU701576B2 (en) 1993-10-22 1999-02-04 Trigen Limited Platelet-derived growth factor analogues
JP2001509030A (ja) * 1997-01-21 2001-07-10 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｆｃレセプターおよびポリペプチド
WO1998032771A1 (fr) * 1997-01-29 1998-07-30 Toray Industries, Inc. Proteines chimeres, complexes heterodimeres de ces proteines et substituant de plaquette
EP1177289B1 (en) 1999-05-07 2008-04-23 Sanofi-Aventis Deutschland GmbH Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
WO2001016321A1 (en) * 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1406929A2 (en) 2001-07-18 2004-04-14 MERCK PATENT GmbH Glycoprotein vi fusion proteins
EP1538165A1 (en) 2003-12-03 2005-06-08 Procorde GmbH Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4

Also Published As

Publication number Publication date
US20160207976A1 (en) 2016-07-21
EP2341141A2 (en) 2011-07-06
ES2304347T3 (es) 2008-10-16
CY1116336T1 (el) 2017-02-08
JP5480457B2 (ja) 2014-04-23
KR100703592B1 (ko) 2007-04-05
HK1045714A1 (en) 2002-12-06
CZ20013989A3 (cs) 2002-02-13
HUP0201049A2 (hu) 2002-07-29
WO2000068377A1 (en) 2000-11-16
DE60038675T2 (de) 2009-07-02
US20070172480A1 (en) 2007-07-26
AU4555500A (en) 2000-11-21
US20070172893A1 (en) 2007-07-26
DK2341141T3 (en) 2015-04-20
PT1177289E (pt) 2008-06-30
JP2011097948A (ja) 2011-05-19
PT2341141E (pt) 2015-04-30
ZA200110071B (en) 2003-03-06
US8198030B2 (en) 2012-06-12
BRPI0010325B1 (pt) 2016-01-19
EP1942186A3 (en) 2008-10-08
CZ302693B6 (cs) 2011-09-07
NO333408B1 (no) 2013-05-27
EP1942186A2 (en) 2008-07-09
NO20015420L (no) 2002-01-03
BR0010325A (pt) 2002-02-26
MXPA01011274A (es) 2002-05-06
AU775952B2 (en) 2004-08-19
EP2341141A3 (en) 2012-03-28
EP2341141B1 (en) 2015-01-14
ES2534652T3 (es) 2015-04-27
CN1253569C (zh) 2006-04-26
KR20010112951A (ko) 2001-12-22
EP1177289B1 (en) 2008-04-23
US7928066B1 (en) 2011-04-19
EP1942186B1 (en) 2017-04-12
CY1108190T1 (el) 2014-02-12
SI1177289T1 (sl) 2008-08-31
AR023848A1 (es) 2002-09-04
PL351437A1 (en) 2003-04-22
HK1045714B (zh) 2006-09-22
EP1177289A1 (en) 2002-02-06
JP2003515313A (ja) 2003-05-07
RU2287580C2 (ru) 2006-11-20
CA2372515A1 (en) 2000-11-16
PL204449B1 (pl) 2010-01-29
US20110237655A1 (en) 2011-09-29
JP5554696B2 (ja) 2014-07-23
US8278430B2 (en) 2012-10-02
DE60038675D1 (de) 2008-06-05
NO20015420D0 (no) 2001-11-06
CA2372515C (en) 2015-12-01
SK15762001A3 (sk) 2002-04-04
ATE393223T1 (de) 2008-05-15
CN1350583A (zh) 2002-05-22

Similar Documents

Publication Publication Date Title
DK1177289T3 (da) Rekombinant blodpladecollagenreceptor glycopotein VI og dets farmaceutiske anvendelse
DE60041782D1 (de) Bioaktiver und osteoporotischer knochenzement
DK1163271T3 (da) Rekombinant IL-18 antistoffer og deres anvendelse
EE200300107A (et) Uued retseptori nukleiinhapped ja polüpeptiidid
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
FR2799638B1 (fr) Fixateur et articulation vertebrale
IS6411A (is) Kaspasa tálmar og notkun þeirra
NO20005990L (no) Platinumkompleks, dets fremstilling og terapeutiske anvendelse
DE60043058D1 (de) Dentalwerkstoffe
NO20012738D0 (no) Terapeutiske produkter og anvendelse derav
NO20005919D0 (no) Platinakompleks, dets fremstilling og terapeutisk anvendelse
ATA1972000A (de) Rekombinant hergestelltes menschliches intestinales npt2b-polypeptid
NO20015068D0 (no) Nya 8A- og 9A-15-medlemmers laktamer
NO20020919D0 (no) Irenprotein, dets fremstilling og anvendelse
NO20023015L (no) Humant heparanasebeslektet polypeptid og nukleinsyre
EP1241257A4 (en) TACHYKININ-SIMILAR POLYPEPTIDES AND ITS APPLICATION
ID27998A (id) Peptida baru untuk penggunaan dalam imunoterapi pada penyakit atau atoimun
NO20015906D0 (no) Spliceosomprotein og dets anvendelse
NO20014300L (no) Nytt protein og dets anvendelse
SE9904414D0 (sv) Pharmaceutical composition and use
SE9803771D0 (sv) Pharmaceutical composition and use
SE9703737D0 (sv) Pharmaceutical composition and use
BR1100391A (pt) Composto e composição farmacêutica
EP1227149A4 (en) New protein and its use
DK1049777T3 (da) ACPL-DNA og -polypeptider